5-S-cysteinyldopamine neurotoxicity: Influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease

Journal of Neuroscience Research

Volumn 92, Issue 3, 2014, Pages 347-358

  Aureli, Cristina ^a   Cassano, Tommaso ^b   Masci, Alessandra ^a   Francioso, Antonio ^a   Martire, Sara ^a   Cocciolo, Annalisa ^a   Chichiarelli, Silvia ^a   Romano, Adele ^a   Gaetani, Silvana ^a   Mancini, Patrizia ^c   Fontana, Mario ^a   d'Erme, Maria ^a,d   Mosca, Luciana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Pasteur Institute   (Italy)

Author keywords

synuclein; 5 S cysteinyldopamine; 6 hydroxydopamine; ERp57; Parkinson's disease

Indexed keywords

5 (S CYSTEINYL)DOPAMINE; ALPHA SYNUCLEIN; CATECHOL; DOPAMINE; ERP57 PROTEIN; GLUTATHIONE; NEUROPEPTIDE; SULFIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; MALE; MOUSE; NERVE DEGENERATION; NEUROBLASTOMA CELL; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CARBONYLATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SYNTHESIS;

5-S-CYSTEINYLDOPAMINE; 6-HYDROXYDOPAMINE; ERP57; PARKINSON'S DISEASE; Α-SYNUCLEIN;

ALPHA-SYNUCLEIN; ANIMALS; BIOGENIC MONOAMINES; BRAIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; GLUTATHIONE DISULFIDE; HUMANS; MALE; MICE; NEUROBLASTOMA; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSON DISEASE; PROTEIN CARBONYLATION; PROTEIN DISULFIDE-ISOMERASES;

EID: 84892480344     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23318     Document Type: Article

References (77)

1. Akazawa YO, Saito Y, Nishio K, Horie M, Kinumi T, Masuo Y, Yoshida Y, Ashida H, Niki E. 2010. Proteomic characterization of the striatum and midbrain treated with 6-hydroxydopamine: alteration of 58-kDa glucose-regulated protein and C/EBP homologous protein. Free Radic Res 44:410-421.
2. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B. 1997. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69:1326-1329.
3. Banhegyi G, Mandl J, Csala M. 2008. Redox-based endoplasmic reticulum dysfunction in neurological diseases. J Neurochem 107:20-34.
4. Bellucci A, Navarria L, Zaltieri M, Falarti E, Bodei S, Sigala S, Battistin L, Spillantini M, Missale C, Spano P. 2011. Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson's disease. J Neurochem 116:588-605.
5. Blandini F, Armentero MT, Martignoni E. 2008. The 6-hydroxydopamine model: news from the past. Parkinsonism Rel Disord 14(Suppl 2):S124-S129.
6. Branchi I, D'Andrea I, Armida M, Carnevale D, Ajmone-Cat MA, Pezzola A, Potenza RL, Morgese MG, Cassano T, Minghetti L, Popoli P, Alleva E. 2010. Striatal 6-OHDA lesion in mice: investigating early neurochemical changes underlying Parkinson's disease. Behav Brain Res 208:137-143.
7. Carstam R, Brinck C, Hindemith-Augustsson A, Rorsman H, Rosengren E. 1991. The neuromelanin of the human substantia nigra. Biochim Biophys Acta 1097:152-160.
8. Cassano T, Gaetani S, Morgese MG, Macheda T, Laconca L, Dipasquale P, Taltavull J, Shippenberg TS, Cuomo V, Gobbi G. 2009. Monoaminergic changes in locus coeruleus and dorsal raphe nucleus following noradrenaline depletion. Neurochem Res 34:1417-1426.
9. Cenci MA, Lundblad M. 2007. Current protocols in neuroscience. New York: John Wiley & Sons. p 9.25.21.
10. Cheng FC, Kuo JS, Chia LG, Dryhurst G. 1996. Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. J Neural Transm 103:433-446.
11. Chichiarelli S, Ferraro A, Altieri F, Eufemi M, Coppari S, Grillo C, Arcangeli V, Turano C. 2007. The stress protein ERp57/GRP58 binds specific DNA sequences in HeLa cells. J Cell Physiol 210:343-351.
12. Chioccara F, Novellino E. 1986. A convenient one step synthesis of 5-cystein-S-yldopa using ceric ammonium nitrate. Synthetic Commun 16:967-971.
13. Coe H, Michalak M. 2010. ERp57, a multifunctional endoplasmic reticulum resident oxidoreductase. Int J Biochem Cell Biol 42:796-799.
14. Dalfo E, Ferrer I. 2008. Early alpha-synuclein lipoxidation in neocortex in Lewy body diseases. Neurobiol Aging 29:408-417.
15. Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron 39:889-909.
16. Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AH, et al. 1994. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 35:38-44.
17. Erickson RR, Dunning LM, Olson DA, Cohen SJ, Davis AT, Wood WG, Kratzke RA, Holtzman JL. 2005. In cerebrospinal fluid ER chaperones ERp57 and calreticulin bind beta-amyloid. Biochem Biophys Res Commun 332:50-57.
18. Fahn S, Cohen G. 1992. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 32:804-812.
19. Ferrer I. 2009. Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects. Prog Neurobiol 88:89-103.
20. Fornstedt B, Brun A, Rosengren E, Carlsson A. 1989. The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J Neural Transm Park Dis Dement Sect 1:279-295.
21. Franklin KBJ, Paxinos G. 2000. The mouse brain in stereotaxic coordinates. San Diego: Academic Press.
22. Goers J, Manning-Bog AB, McCormack AL, Millett IS, Doniach S, Di Monte DA, Uversky VN, Fink AL. 2003. Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 42:8465-8471.
23. Hetz C, Russelakis-Carneiro M, Walchli S, Carboni S, Vial-Knecht E, Maundrell K, Castilla J, Soto C. 2005. The disulfide isomerase Grp58 is a protective factor against prion neurotoxicity. J Neurosci 25:2793-2802.
24. Hissin PJ, Hilf R. 1976. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74:214-226.
25. Holtz WA, O'Malley KL. 2003. Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J Biol Chem 278:19367-19377.
26. Holtz WA, Turetzky JM, Jong YJ, O'Malley KL. 2006. Oxidative stress-triggered unfolded protein response is upstream of intrinsic cell death evoked by parkinsonian mimetics. J Neurochem 99:54-69.
27. Ito S, Fujita K, Yoshioka M, Sienko D, Nagatsu T. 1986. Identification of 5-S- and 2-S-cysteinyldopamine and 5-S-glutathionyldopamine formed from dopamine by high-performance liquid-chromatography with electrochemical detection. J Chromatogr 375:134-140.
28. +-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J Biol Chem 279:15240-15247.
29. Kholodilov NG, Oo TF, Burke RE. 1999. Synuclein expression is decreased in rat substantia nigra following induction of apoptosis by intrastriatal 6-hydroxydopamine. Neurosci Lett 275:105-108.
30. Kim-Han JS, O'Malley KL. 2007. Cell stress induced by the parkinsonian mimetic, 6-hydroxydopamine, is concurrent with oxidation of the chaperone, ERp57, and aggresome formation. Antiox Redox Signal 9:2255-2264.
31. Kontopoulos E, Parvin JD, Feany MB. 2006. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15:3012-3023.
32. Krishnan S, Chi EY, Wood SJ, Kendrick BS, Li C, Garzon-Rodriguez W, Wypych J, Randolph TW, Narhi LO, Biere AL, Citron M, Carpenter JF. 2003. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry 42:829-837.
33. Li H, Dryhurst G. 1997. Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3, 4-dihydro-5-hydroxy-2H-1, 4-benzothiazine-3-carboxyli c acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease. J Neurochem 69:1530-1541.
34. Li H, Dryhurst G. 2001. Oxidative metabolites of 5-S-cysteinyldopamine inhibit the pyruvate dehydrogenase complex. J Neural Transm 108:1363-1374.
35. Martin HL, Teismann P. 2009. Glutathione-a review on its role and significance in Parkinson's disease. FASEB J 23:3263-3272.
36. Miller RL, James-Kracke M, Sun GY, Sun AY. 2009. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 34:55-65.
37. Montine KS, Sidell KR, Zhang J, Montine TJ. 2002. Dopamine thioethers: formation in brain and neurotoxicity. Neurotox Res 4:663-669.
38. Mosca L, Foppoli C, Coccia R, Rosei MA. 1996. Pheomelanin production by the lipoxygenase-catalyzed oxidation of 5-S-cysteinyldopa and 5-S-cysteinyldopamine. Pigment Cell Res 9:117-125.
39. Mosca L, Lendaro E, d'Erme M, Marcellini S, Moretti S, Rosei MA. 2006. 5-S-cysteinyl-dopamine effect on the human dopaminergic neuroblastoma cell line SH-SY5Y. Neurochem Int 49:262-269.
40. Mosca L, Tempera I, Lendaro E, Di Francesco L, d'Erme M. 2008. Characterization of catechol-thioether-induced apoptosis in human SH-SY5Y neuroblastoma cells. J Neurosci Res 86:954-960.
41. Muller T, Muhlack S. 2012. Cysteine decrease following acute Levodopa intake in patients with Parkinson's disease. Neurosci Lett 521:37-39.
42. + but not 6-OHDA induced cell death in dopaminergic neurons. Neurobiol Dis 14:43-51.
43. Olanow CW, Tatton WG. 1999. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22:123-144.
44. Perez RG, Hastings TG. 2004. Could a loss of alpha-synuclein function put dopaminergic neurons at risk? J Neurochem 89:1318-1324.
45. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
46. Rao RV, Bredesen DE. 2004. Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. Curr Opin Cell Biol 16:653-662.
47. Reiter RJ, Manchester LC, Tan DX. 2010. Neurotoxins: free radical mechanisms and melatonin protection. Curr Neuropharmacol 8:194-210.
48. Rosengren E, Linder-Eliasson E, Carlsson A. 1985. Detection of 5-S-cysteinyldopamine in human brain. J Neural Transm 63:247-253.
49. Ryu EJ, Harding HP, Angelastro JM, Vitolo OV, Ron D, Greene LA. 2002. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J Neurosci 22:10690-10698.
50. Ryu EJ, Angelastro JM, Greene LA. 2005. Analysis of gene expression changes in a cellular model of Parkinson disease. Neurobiol Dis 18:54-74.
51. Salauze L, van der Velden C, Lagroye I, Veyret B, Geffard M. 2005. Circulating antibodies to cysteinyl catecholamines in amyotrophic lateral sclerosis and Parkinson's disease patients. Amyotroph Lateral Scler Other Motor Neuron Disord 6:226-233.
52. Sangchot P, Sharma S, Chetsawang B, Porter J, Govitrapong P, Ebadi M. 2002. Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture. Dev Neurosci 24:143-153.
53. Shavali S, Carlson EC, Swinscoe JC, Ebadi M. 2004. 1-Benzyl-1, 2, 3, 4-tetrahydroisoquinoline, a Parkinsonism-inducing endogenous toxin, increases alpha-synuclein expression and causes nuclear damage in human dopaminergic cells. J Neurosci Res 76:563-571.
54. Shen XM, Dryhurst G. 1996. Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. Chem Res Toxicol 9:751-763.
55. Shen XM, Zhang F, Dryhurst G. 1997. Oxidation of dopamine in the presence of cysteine: characterization of new toxic products. Chem Res Toxicol 10:147-155.
56. Shen XM, Li H, Dryhurst G. 2000. Oxidative metabolites of 5-S-cysteinyldopamine inhibit the alpha-ketoglutarate dehydrogenase complex: possible relevance to the pathogenesis of Parkinson's disease. J Neural Transm 107:959-978.
57. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD. 1994a. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348-355.
58. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. 1994b. Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 36:356-361.
59. Sidell KR, Olson SJ, Ou JJ, Zhang Y, Amarnath V, Montine TJ. 2001. Cysteine and mercapturate conjugates of oxidized dopamine are in human striatum but only the cysteine conjugate impedes dopamine trafficking in vitro and in vivo. J Neurochem 79:510-521.
60. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. 2003. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302:841.
61. Smith WW, Jiang H, Pei Z, Tanaka Y, Morita H, Sawa A, Dawson VL, Dawson TM, Ross CA. 2005. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet 14:3801-3811.
62. Sofic E, Lange KW, Jellinger K, Riederer P. 1992. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142:128-130.
63. Spencer JP, Jenner P, Daniel SE, Lees AJ, Marsden DC, Halliwell B. 1998. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 71:2112-2122.
64. Spencer JP, Whiteman M, Jenner P, Halliwell B. 2002. 5-S-cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. J Neurochem 81:122-129.
65. Sultana R, Perluigi M, Butterfield DA. 2009. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol 118:131-150.
66. Uversky VN. 2007. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem 103:17-37.
67. Venda LL, Cragg SJ, Buchman VL, Wade-Martins R. 2010. Alpha-synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci 33:559-568.
68. Verina T, Schneider JS, Guilarte TR. 2013. Manganese exposure induces alpha-synuclein aggregation in the frontal cortex of non-human primates. Toxicol Lett 217:177-183.
69. Wang HQ, Takahashi R. 2007. Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's disease. Antiox Redox Signal 9:553-561.
70. Wilhelmus MM, Verhaar R, Andringa G, Bol JG, Cras P, Shan L, Hoozemans JJ, Drukarch B. 2010. Presence of tissue transglutaminase in granular endoplasmic reticulum is characteristic of melanized neurons in Parkinson's disease brain. Brain Pathol 21:130-139.
71. Xie HR, Hu LS, Li GY. 2010. SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin Med J (Engl) 123:1086-1092.
72. Xu S, Zhou M, Yu S, Cai Y, Zhang A, Ueda K, Chan P. 2006. Oxidative stress induces nuclear translocation of C-terminus of alpha-synuclein in dopaminergic cells. Biochem Biophys Res Commun 342:330-335.
73. Zecca L, Tampellini D, Gerlach M, Riederer P, Fariello RG, Sulzer D. 2001. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol 54:414-418.
74. Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D. 2002. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett 510:216-220.
75. Zhang F, Dryhurst G. 1994. Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. J Med Chem 37:1084-1098.
76. Zhang F, Dryhurst G. 1995. Reactions of cysteine and cysteinyl derivatives with dopamine-O-quinone and further insights into the oxidation chemistry of 5-S-cysteinyldopamine-potential relevance to idiopathic Parkinson's disease. Bioorg Chem 23:193-216.
77. Zucca FA, Giaveri G, Gallorini M, Albertini A, Toscani M, Pezzoli G, Lucius R, Wilms H, Sulzer D, Ito S, Wakamatsu K, Zecca L. 2004. The neuromelanin of human substantia nigra: physiological and pathogenic aspects. Pigment Cell Res 17:610-617.